Study: Ozempic Cuts Heart Disease Risk by 20% Regardless of Weight Loss

Published 8 hours ago·Updated 7 hours ago

story

Above: A mounjaro injection pen and some scales on Oct. 8, 2025, in London, U.K. Image copyright: Peter Dazeley/Getty Images

The Spin

Narrative A

GLP-1 drugs represent a revolutionary breakthrough that transforms obesity treatment and delivers extraordinary health benefits beyond weight loss. These medications reduce risks of dementia, addiction, heart disease, and dozens of other conditions by 10-20%, offering hope for previously untreatable diseases. The drugs energize medical research and prove obesity is a biological condition requiring chronic treatment.

Axios Guardian

Narrative B

GLP-1 drugs like Ozempic aren't miracle cures and come with serious risks that outweigh their modest benefits. These medications cause dangerous complications including pancreatitis, kidney problems, and semi-starvation states where patients eat as few as 600 calories daily. Most people regain 60-70% of lost weight after stopping, making them ineffective long-term solutions to obesity and associated conditions.

SciTech Daily RNZ